Unilateral vs bilateral symptomatic knee osteoarthritis: associations between pain intensity and function

Knee osteoarthritis is a degenerative "wear and tear" disorder affecting mainly population over 50 years old. It can also present in younger people, especially after an injury or as a part of other diseases. While many therapeutic options exist for knee osteoarthritis, none of them has the potential to cure this condition. Cellular Matrix represents a combination of natural non-crosslinked hyaluronic acid (HA), thixotropic cell separation gel, and sodium citrate anticoagulant solution. A combination of Cellular Matrix with autologous platelet-rich plasma (A-PRP) is a novel therapeutic approach to the management of knee osteoarthritis. It is assumed that the active components HA and PRP have a synergistic effect contributing to a better therapeutic outcome in patients with knee osteoarthritis. Physiotherapy could provide an additional benefit. This is a retrospective pilot study assessing the potential benefit of Cellular Matrix and A-PRP combined with physiotherapy in the management of chronic knee osteoarthritis. Twenty-five patients were enrolled in the study and injected with three doses of Cellular Matrix combined with A-PRP with a time span of 2 weeks between each injection. All patients received standardized physiotherapy. The results showed that 68% of patients achieved more than 50% improvement in pain, stiffness, and function of the knee joints. There were no adverse reactions. This retrospective pilot study confirmed the positive effect of PRP and HA combination in the management of mild and moderate knee osteoarthritis. These preliminary results need to be verified in randomized control trials.

Download Full-text

The association between patella alignment and knee pain and function: an MRI study in persons with symptomatic knee osteoarthritis

Osteoarthritis and Cartilage ◽

10.1016/j.joca.2007.04.014 ◽

2007 ◽

Vol 15 (11) ◽

pp. 1235-1240 ◽

Cited By ~ 33

Author(s):

L. Kalichman ◽

Y. Zhu ◽

Y. Zhang ◽

J. Niu ◽

D. Gale ◽

...

Keyword(s):

Knee Osteoarthritis ◽

Knee Pain ◽

Symptomatic Knee Osteoarthritis ◽

Symptomatic Knee ◽

Mri Study ◽

And Function

Download Full-text

Effects of therapeutic alliance on clinical outcomes in patients with symptomatic knee osteoarthritis undergoing an exercise program: A randomized clinical trial protocol

Medwave ◽

10.5867/medwave.2021.03.8159 ◽

2021 ◽

Vol 21 (03) ◽

pp. e8159-e8159

Author(s):

Iván Cuyul-Vásquez ◽

Jorge Fuentes C

Keyword(s):

Clinical Trial ◽

Knee Osteoarthritis ◽

Therapeutic Alliance ◽

Pain Intensity ◽

Physical Therapists ◽

Exercise Program ◽

Therapeutic Exercise ◽

Pressure Pain ◽

Symptomatic Knee Osteoarthritis ◽

Symptomatic Knee

Background Previous evidence has shown that seniors physical therapists applying electrotherapy and an enhanced therapeutic alliance in their sessions can positively influence the levels of analgesia of patients with chronic low back pain. It is currently unknown if these effects can be achieved in people with symptomatic knee osteoarthritis when receiving treatment focused on therapeutic exercise. Aim To determine the effects of different therapeutic alliance levels during the application of a therapeutic exercise program on pain intensity and pressure pain threshold in patients with symptomatic knee osteoarthritis. Method This will be a randomized, parallel, two-arm, clinical trial. An intervention of three sessions of therapeutic exercise will be applied for one week. Patients aged 45 to 65 years old with a clinical and radiographic diagnosis of knee osteoarthritis will participate. Also, patients with a pain intensity of at least three months duration and 3 to 8 points in a numerical rating scale will be included. Patients will be randomly assigned to a therapeutic exercise experimental group with an enhanced therapeutic alliance (e.g., active listening, personalized conversation, empathy) or limited therapeutic alliance (e.g., one-way verbalization, brief interaction). Physical therapists will be trained in delivering these two levels of the therapeutic alliance. The pressure pain thresholds at the symptomatic knee and the pain intensity will be measured before and after the intervention. Discussion The results of this research will determine the impact of the therapeutic alliance as a nonspecific relevant factor during the application of a therapeutic exercise program in the treatment of patients with symptomatic knee osteoarthritis. Clinical trials registration number NCT04390932

Download Full-text

Zoledronic acid plus methylprednisolone versus zoledronic acid or placebo in symptomatic knee osteoarthritis: a randomized controlled trial

Therapeutic Advances in Musculoskeletal Disease ◽

10.1177/1759720x19880054 ◽

2019 ◽

Vol 11 ◽

pp. 1759720X1988005 ◽

Cited By ~ 3

Author(s):

Guoqi Cai ◽

Laura L Laslett ◽

Dawn Aitken ◽

Flavia Cicuttini ◽

Lyn March ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Zoledronic Acid ◽

Knee Osteoarthritis ◽

Knee Pain ◽

Controlled Trial ◽

Intravenous Methylprednisolone ◽

Randomized Controlled ◽

Symptomatic Knee Osteoarthritis ◽

Symptomatic Knee ◽

And Function

Background: The aim of this study was to compare the efficacy and safety of zoledronic acid (ZA) plus intravenous methylprednisolone (VOLT01) to ZA, and placebo for knee osteoarthritis. Methods: A single-center, double-blind, randomized controlled trial (RCT) was carried out. Adults (aged ⩾50 years) with knee osteoarthritis, significant knee pain [⩾40 mm on a 100 mm visual analog scale (VAS)], and magnetic resonance imaging-detected bone marrow lesion (BML) were randomized to receive a one-off administration of VOLT01, ZA, or placebo. The primary hypothesis was that VOLT01 was superior to ZA in having a lower incidence of acute phase responses (APRs) over 3 days. Secondary hypotheses were that VOLT01 was noninferior to ZA, and both treatments were superior to placebo in decreasing BML size over 6 months and in improving knee pain [Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and VAS] and function (WOMAC) over 3 and 6 months. Results: A total of 117 patients (62.2 ± 8.1 years, 63 women) were enrolled. The incidence of APRs was similar in the VOLT01 (90%) and ZA (87%) groups ( p = 0.74). VOLT01 was superior to ZA in improving knee pain and function after 6 months and noninferior to ZA in reducing BML size. However, BML size change was small in all groups and there were no between-group differences. Compared with placebo, VOLT01 but not ZA improved knee function and showed a trend toward improving knee pain after 6 months. Conclusions: Administering intravenous methylprednisolone with ZA did not reduce APRs or change knee BML size over 6 months, but in contrast to ZA or placebo, it may have a beneficial effect on symptoms in knee osteoarthritis. Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12613000039785.

Download Full-text